Alzheimer's Disease and Advanced Drug Delivery Strategies

1st Edition - November 30, 2023
Editors: Bhupendra Prajapati, Dinesh Kumar Chellappan, Prakash Kendre
Language: English
Paperback ISBN:
9 7 8 - 0 - 4 4 3 - 1 3 2 0 5 - 6
eBook ISBN:
9 7 8 - 0 - 4 4 3 - 1 3 2 0 6 - 3

Alzheimer's Disease and Advanced Drug Delivery Strategies compiles under a single volume the most recent advances in drug delivery to the brain as related to AD treatment… Read more

Purchase options

Limited Offer

Save 50% on book bundles

Immediately download your ebook while waiting for your print delivery. No promo code is needed.

Institutional subscription on ScienceDirect

Request a sales quote

Alzheimer's Disease and Advanced Drug Delivery Strategies compiles under a single volume the most recent advances in drug delivery to the brain as related to AD treatment. The book's editors recruited scientists from around the world to produce high quality chapters covering not only nanotechnological approaches, but also microsphere, niosomes, and liposomes. Among the topics covered are synthetic molecules, nobiletin, nose to brain delivery, natural biomaterials, cationic nanoformulations, dendrimers, microbubbles, and more. This book represents a complete reference for academic and corporate pharma researchers investigating targeted drug delivery to the brain.

Cover image
Title page
Table of Contents
Copyright
Contributors
About the editors
Preface
Acknowledgments
Chapter 1. Etiology, pathogenesis of Alzheimer's disease and amyloid beta hypothesis
1. Introduction
2. Etiology of Alzheimer's disease
3. Pathogenesis of Alzheimer's disease
4. Diagnosis of AD
5. Amyloid beta protein hypothesis
6. Consequences of amyloid beta (Aβ) formation
7. Genetic factors responsible for the Alzheimer's disease
Chapter 2. Neuroinflammation in Alzheimer's disease
1. Introduction
2. History of neuroinflammation in AD
3. The concept of neuroinflammation in AD
4. Neuroinflammation: Causes and consequences of Alzheimer's disease
5. BBB integrity and neuroinflammation
6. Role of cellular players
7. Role of mediators and modulators in neuroinflammation
8. Role of intracellular signaling pathway
9. Genetic studies
10. Imaging of neuroinflammation in AD
11. Possible intervention of neuroinflammation in AD
12. Factors associated with neuroinflammation
13. Development of therapeutic potential
14. Conclusion
Chapter 3. Recent updates in chemistry of Alzheimer's: Synthetic molecules
1. Introduction
2. MTDL approach associated with following scaffold or structures
3. Conclusion
Chapter 4. Blood brain barrier and its significance in drug delivery to brain in Alzheimer disease
1. Introduction
2. Blood brain barrier
3. Current treatments for AD
4. Emerging therapies for AD
5. Nanotherapeutics for AD
6. Other approaches for crossing BBB
7. Conclusion and future perspective
Chapter 5. Nose to brain delivery for the treatment of Alzheimer's disease
1. Introduction
2. The nose-to-brain (N2B) pathway
3. AZD and current treament
4. Development of N2B delivery for AZD
5. Approaches to modulation of N2B delivery in AZD
6. Advantages of N2B delivery for AZD
7. Conclusion and future directions
Chapter 6. Amyloid cascade hypothesis, tau synthesis, and role of oxidative stress in AD
1. Introduction to the amyloid (amyloid-beta peptide)
2. Biogenesis of amyloid-beta
3. Amyloid cascade hypothesis (ACH)
4. Pros and cons of the ACH
5. Therapeutic targeting for amyloid-beta in Alzheimer's pathogenesis
6. Tau protein
7. Role of oxidative stress in AD
8. Corelation of amyloid B protein, tau process, and oxidative stress in AD
Chapter 7. New biologicals and biomaterials in the therapy of Alzheimer's disease
1. Introduction
2. Potential target for Alzheimer's disease therapy
3. Biologicals used in therapy of Alzheimer's disease
4. Biomaterials used in therapy of Alzheimer's disease
5. Nanoparticles in the therapy of Alzheimer's disease
6. Metal nanoparticles for Alzheimer's disease treatment
7. Other NPs
8. Systems based on biomaterials for mass production of therapeutic cells
9. Challenges of biomaterial-based drug delivery approach in Alzheimer's disease
10. Conclusion
Chapter 8. Roles of nano medicine in diagnosis of Alzheimer's disease
1. Introduction
2. Diagnostic tools for AD
3. Future perspective of nano medicine and their effectiveness
4. Conclusion and limitations
Chapter 9. Nanotechnology-based delivery for CRISPR-Cas 9 cargo in Alzheimer's disease
1. Introduction
2. Genome editing by CRISPR-Cas system
3. Genome editing targets and scope of CRISPR-Cas 9 technology in Alzheimer's disease
4. Barriers and challenges to CRISPR-Cas 9 delivery
5. Synergizing nano and CRISPR: Nanocarrier-mediated delivery
6. Conclusions and prospects
Chapter 10. Liposomes as carrier for drug delivery in Alzheimer's disease
1. Introduction
2. Liposomes as nanocarrier system for drug delivery
3. Liposome preparation materials and process
4. Modification of liposomes
5. Liposome's potential as drug delivery for AD
6. Conclusion
Chapter 11. PLGA mediated drug delivery for Alzheimer's disease
1. Introduction
2. PLGA in Alzheimer's disease
3. Applications of PLGA in treatment of AD
4. Animal models for testing AD targeted PLGA formulations
5. Patents
6. Conclusion and future prospective
Chapter 12. Regulatory and ethical concerns in the use of nanomaterials
1. Introduction
2. Nanomaterials
3. Existing regulations on nanomaterials
4. Regulatory concerns involved with the use of nanomaterials
5. Nanomaterials in formulations and drug delivery systems to treat Alzheimer (AD)
6. Ethical concerns involved with the use of nanomaterials
7. Future challenges and policies
Chapter 13. Symptoms and conventional treatments of Alzheimer's disease
1. Introduction
2. Recent neuropathological aspects
3. Clinical presentation
4. Conventional therapeutic approaches
5. Hardships faced by caregivers
6. Need of treatments although AD is incurable
7. Recent advances in AD treatments
8. Conclusion and outlooks
Chapter 14. Dendrimers in the management of Alzheimer's disease
1. Introduction
2. Synthesis method of dendrimers
3. Types of dendrimers
4. Method of drug loading in dendrimers
5. Properties of dendrimers
6. Characterization of dendrimers
7. Animal models: In vitro and in vivo studies
8. Applications in treatment of Alzheimer's disease
9. Clinical trials
10. Patents
11. Conclusion
Chapter 15. Precision medicines for the treatment of Alzheimer's disease
1. Introduction
2. Background
3. Comprehensive risk determination
4. Intervention design
5. Methodology
6. System biology method for AD research
7. Role of genetics in precision medicine
8. Nanoparticles as precision medicines in AD
9. Discovery, development, and validation of pathophysiological biomarker candidates in AD
10. Challenges in AD risk reduction
11. Next step and future directions
12. Conclusion
Chapter 16. Nanoformulations targeting Alzheimer's disease
1. Introduction
2. Overview of BBB and B-CSFB
3. Obstacles in drug delivery to BBB/B-CSF in ADs
4. Nanocarrier based nanoformulations to combat AD's
5. Carbon dots (CDs)
6. Nanodiamonds (NDs)
7. Fullerene
8. Nanotubes
9. Conclusion
Chapter 17. Lipid nanoparticles in targeting Alzheimer's disease
1. Introduction
2. Different types of LNs used in AD
3. Lipids nanoparticles (LNs) and AD
4. Limitations of LNs in CNS diseases
5. Regulatory considerations of LNs
6. Future prospective and conclusion
Chapter 18. Novel therapeutic approaches for targeting Alzheimer’s disease
1. Alzheimer's disease: Scope of new therapeutic approaches
2. FDA approved drugs for Alzheimer's disease
3. Novel therapeutic approaches
4. Conclusion and future perspectives
Chapter 19. Micro and nanoemulsion as drug carriers in Alzheimer's disease
1. Introduction
2. Microemulsion and nanoemulsion formulation
3. Physicochemical characterization of formulations
4. Applications, current research and patent landscape of microemulsions and nanoemulsion
5. Pharmacokinetics and pharmacodynamic of developed NE/ME for AD
6. Conclusion and future perspectives
Chapter 20. Targeted nanotechnology-based formulations
1. Introduction
2. Nanomaterials
3. Targeted nanotechnology-based formulations (TNbF)
4. Applications of targeted nanoformulations
5. Concerns in the design and application of nanoformulations
6. Clinical data
7. Prospects in the design of targeted nanoformulation
8. Conclusion
Chapter 21. Drug delivery for Alzheimer's disease using nanotechnology: Challenges and advancements
1. Introduction
2. Drug delivery strategies for Alzheimer diseases
3. Alzheimer's disease clinical requirement and drug delivery challenges
4. Nanomedicine as future aspect in treatment of Alzheimer diseases
5. Nonmicellar based formulation
6. Dendrimers
7. Nanogels
8. Alzheimer diseases treatment with lipid-based nanoparticles
9. Metallic nanoparticles
10. Nanoparticulate-chelation-based Alzheimer diseases therapy
11. Nanomedicine theranostics formulations
12. Protein-coated nanoparticles
13. Antibody decorated nanoparticles
14. Novel biomarkers used in diagnosis of Alzheimer diseases
15. Conclusion and future perspective
Chapter 22. Current trends and updates in the treatment of Alzheimer's disease
1. Introduction
2. Pathophysiology and multifactorial nature of AD
3. Current treatment approaches for AD
4. Potential therapeutic strategies for AD
5. Conclusion and perspective
Chapter 23. Pharmacokinetics and pharmacodynamics of various novel formulations targeting Alzheimer's disease
1. Introduction
2. Alzheimer's disease
3. Currently available drug molecules for the management for AD
4. Treatments for AD in the CNS: Clinical pharmacokinetics and pharmacodynamics
5. Nanoparticle delivery system for the management of AD and their PK PD
6. Conclusion
Chapter 24. Microbubbles-based drug delivery for antiAlzheimer's drugs
1. Introduction
2. Ultrasound mediated microbubble therapy to overcome BBB for treating Alzheimer's patients
3. Drug loaded lipid based microbubbles for AD
4. In vitro cell models of BBB for AD and microbubble-mediated drug delivery
5. Clinical trials of microbubble-based drug delivery for treatment of AD
6. Challenges and toxicity concerns of microbubble-based drug delivery for AD
7. Future aspects and conclusion
Chapter 25. Neurotoxicity with the use of nanomaterials
1. Introduction
2. Toxicity associated with nanomaterials
3. Brain as nanoparticles target
4. Properties of nanoparticles that influence toxicities
5. Mechanisms of neurotoxicity
6. Mitochondrial dysfunction due to nanoparticles
7. DNA damage due to nanoparticles
8. Endocrine dysfunction due to nanoparticles
9. Conclusion
Chapter 26. Combinatorial therapy in Alzheimer's disease
1. Introduction
2. Diagnostic criteria for Alzheimer's disease
3. Combinatorial treatment strategies for Alzheimer's disease
4. On-going clinical trialon AD
5. Summary
Index

Bhupendra Prajapati

Dr. Prajapati is a Professor in Department of Pharmaceutics, Shree S.K.Patel College of Pharmaceutical Education and Research, Ganpat University, Gujarat, India. He has more than 20 years of academic and research experience, has published more than 100 research and review papers in international and national Journals. Under his editorial two book under process and he authored 20 book chapters in the field of novel drug delivery. He published two Indian patent and three application under evaluation. He is a reviewer in three high impact journals and is on the editorial board of several scientific journals.

Affiliations and expertise

Professor, Dept. of Pharmaceutics and Pharmaceutical Technology, Shree S.K. Patel College of Pharmaceutical Education & Research, Faculty of Pharmacy, Ganpat University

Dinesh Kumar Chellappan

Dr. Chellappan is presently affiliated to the International Medical University (IMU), Kuala Lumpur, Malaysia. He boasts more than 18 years of active teaching experience in the current profession. In 2009, he completed his PhD in Pharmaceutical Sciences, from the prestigious Manipal University, India. His major research area has been inflammation in biological systems. He has published more than 250 publications in reputed research journals with a cumulative impact factor of >600. In addition, he is a reviewer for several high impact journals and is on the editorial board of several reputed scientific journals.

Affiliations and expertise

Programme Director, Department of Life Sciences, School of Pharmacy, Medical University (IMU), Kuala Lumpur, Malaysia.

Prakash Kendre

Dr. Kendre currently serving as Vice-Principal and head of the Department of Pharmaceutics at Rajarshi Shahu College of Pharmacy in Buldana, Maharashtra, India. He has more than 17 years of academic, research and industrial experience. He published more than 60 research articles. He published an Indian patent and a number of book chapters with reputable publishing houses.

Affiliations and expertise

Vice-Principal and head, Department of Pharmaceutics, Rajarshi Shahu College of Pharmacy, Buldana, Maharashtra, India.